Shenmai Injection Reduces Cardiomyocyte Apoptosis Induced by Doxorubicin through miR-30a/Bcl-2
中国结合医学杂志(英文版)2025年31卷第3期 页码:240-250
Affiliations:
1.Department of Cardiovascular Medicine, National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing (100091), China
2.Department of Integrated Traditional Chinese and Western Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin (300060), China
3.Department of Cardiovascular Medicine, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin (300193), China
4.Department of Cardiovascular Medicine, Tianjin Key Laboratory of Traditional Research of Traditional Chinese Medicine Prescription and Syndrome, Tianjin (300193), China
Author bio:
Prof. LIU Long-tao, E-mail: liulongtao1976@126.com
Funds:
the National Natural Science Foundation of China(81904118);Hospital Capability Enhancement Project of Xiyuan Hospital, China Academy of Chinese Medical Sciences(XYZX0201-09);the Special Programme for the Cultivation of Outstanding Young Scientific and Technological Talents of the China Academy of Chinese Medical Sciences(ZZ17-YQ-005)
ZHANG Xiao-nan, LI Yan-yang, LYU Shi-chao, et al. Shenmai Injection Reduces Cardiomyocyte Apoptosis Induced by Doxorubicin through miR-30a/Bcl-2[J]. Chinese journal of integrative medicine, 2025, 31(3): 240-250.
ZHANG Xiao-nan, LI Yan-yang, LYU Shi-chao, et al. Shenmai Injection Reduces Cardiomyocyte Apoptosis Induced by Doxorubicin through miR-30a/Bcl-2[J]. Chinese journal of integrative medicine, 2025, 31(3): 240-250. DOI: 10.1007/s11655-025-4005-8.
To explore the molecular mechanism of Shenmai Injection (SMI) against doxorubicin (DOX) induced cardiomyocyte apoptosis.
Methods:
2
A total of 40 specific pathogen-free (SPF) male Sprague Dawley (SD) male rats were divided into 5 groups based on the random number table
including the control group
the model group
miR-30a agomir group
SMI low-dose (SMI-L) group
and SMI high-dose (SMI-H) group
with 8 rats in each group. Except for the control group
the rats were injected weekly with DOX (2 mg/kg) in the tail vein for 4 weeks to induce myocardial injury
and were given different regimens of continuous intervention for 2 weeks. Cardiac function was detected by echocardiography and myocardial pathological changes were observed by Van Gieson (VG) staining. Myocardial injury serum markers
and growth differentiation factor-15 (GDF-15) were detected by enzyme linked immunosorbent assay (ELISA). Cardiomyocyte apoptosis was observed by terminal deoxynucleotidyl transferase-mediated biotinylated dUTP triphosphate nick end labeling (TUNEL) and transmission electron microscopy
and the expressions of target proteins and mRNA were detected by Western blot and quantitative real time polymerase chain reaction (qRT-RCR)
respectively.
Results:
2
The treatment with different doses of SMI reduced rat heart mass index and left ventricular mass index (
P
<
0.05)
significantly improved the left ventricular ejection fraction (
P
<
0.05)
decreased the levels of serum CK
LDH
cTnT
and NT-proBNP (
P
<
0.05 or
P
<
0.01)
reduced the levels of serum sST2 and GDF-15 (
P
<
0.05 or
P
<
0.01)
decreased the collagen volume fraction
reduced the expressions of rat myocardial type Ⅰ and type Ⅲ collagen (
P
<
0.05 or
P
<
0.01)
and effectively alleviated myocardial fibrosis. And the study found that SMI promoted the expression levels of miR-30a and Bcl-2 in myocardium
and down-regulated the expression of Bax
which inhibited the activation of Caspase-3 and Caspase-9 (
P
<
0.05 or
P
<
0.01)
and improved myocardial cell apoptosis.
Conclusions:
2
SMI can alleviate myocardial injury and apoptosis caused by DOX
and its mechanism possibly by promoting the targeted expression of myocardial Bcl-2 protein through miR-30a.